李慧

学历:博士研究生

职称:副研究员、主治医师

职务:附属肿瘤医院肝胆胰肿瘤中心副主任

研究方向:肝胆胰肿瘤

学术任职

重庆市中青年医学高端人才

新重庆青年创新人才

重庆市青年岗位能手

学习经历

1. 2025.01-2025.12 美国弗吉尼亚州立大学 访问学者

2. 2018.09-2021.07 四川大学华西医院外科学 博士

3. 2015.09-2018.07中山大学附属第三医院外科学 硕士

4. 2009.09-2014.07 南昌大学江西医学院临床医学 学士


工作经历

1. 2024.01-至今 重庆大学附属肿瘤医院肝胆胰肿瘤中心 副主任、副研究员、主治医师

2. 2022.07-2023.12 重庆大学附属肿瘤医院肝胆胰肿瘤中心 主治医师

3. 2021.10-2022.06 重庆大学附属肿瘤医院肝胆胰肿瘤中心 医师


研究方向、教学课程

研究方向、教学课程

1.肝胆胰肿瘤恶性进展的表观调控机制;

2.肝纤维化及再生的调控机制;

3.生物材料及人工智能在肝癌诊疗中的转化应用


成果


一、文章(*第一作者, #通讯作者)


1. Li H, Song M, Hylemon PB, Zhou H. LECT2-PHB2 axis: a new mechanistic insight and therapeutic opportunity in alcohol-associated hepatitis. Gut. 2025 May 13:gutjnl-2025-335259.

2. Li H*, Lan T*, Liu H*, Liu C, Dai J, Xu L, Cai Y, Hou G, Xie K, Liao M, Li J, Huang J, Yuan K#, Wang G#, Zeng Y#, Wu H#. IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma. Hepatology. 2022 Jun;75(6):1402-1419.

3. Li H*, Lan T*, Xu L*, Liu H*, Wang J, Li J, Chen X, Huang J, Li X, Yuan K, Zeng Y, Wu H. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner. J Exp Clin Cancer Res. 2020 Jul 6;39(1):128.

4. Li H*, Liu H*, Fu H*, Li J, Xu L, Wang G and Wu H (2021) Peritumoral Tertiary Lymphoid Structures Correlate With Protective Immunity and Improved Prognosis in Patients With Hepatocellular Carcinoma. Front. Immunol. 2021 May 26;12:648812.

5. Li H*, Dai J*, Lan T*, Liu H, Wang J, Cai B, Xu L, Yuan K, Wang G, Wu H. Combination of albumin-globulin score and skeletal muscle index predicts long-term outcomes of intrahepatic cholangiocarcinoma patients after curative resection. Clin Nutr. 2021 May 3;40(6):3891-3900.

6. Wang Y*, Wang S*, Liu M*, Zhang C, Huang Z, Dai F#, Li D#, Li H#. The function of NAT10-driven N4-acetylcytidine modification in cancer: novel insights and potential therapeutic targets. Cell Biosci. 2025 Nov 28;15(1):165.

7. Cheng Y, Gong Y, Li X, Zeng F, Liu B, Chen W, Zhang F, Chen H, Zhu W, Li H#, Zhou L#, Wu T#, Zhou W#. A spreadable self-gelling hemostatic powder sensitizes CAR-NK cell therapy to prevent hepatocellular carcinoma recurrence postresection. J Nanobiotechnology. 2025 May 16;23(1):353.

8. Zhu J*, Wang D*, Liu C, Huang R, Gao F, Feng X, Lan T#, Li H#, Wu H#. Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: A multicenter study. Front Immunol. 2023 Mar 31;14:1165510.

9. Lan T*, Li H*, Zhang D*, Xu L, Liu H, Hao X, Yan X, Liao H, Chen X, Xie K, Li J, Liao M, Huang J, Yuan K, Zeng Y, Wu H. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Mol Cancer. 2019 Dec 19;18(1):186.

10. Liu H*, Lan T*, Li H*, Xu L, Chen X, Liao H, Chen X, Du J, Cai Y, Wang J, Li X, Huang J, Yuan K, Zeng Y. Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR. Theranostics. 2021 Jan 1;11(3):1396-1411. doi: 10.7150/thno.53227.

11. Cai Y*, Lyu T*, Li H*, Liu C, Xie K, Xu L, Li W, Liu H, Zhu J, Lyu Y, Feng X, Lan T, Yang J, Wu H. LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC. J Exp Clin Cancer Res. 2022 Dec 6;41(1):335.

12. Zheng J*, Li H*, He L*, Huang Y*, Cai J, Chen L, Zhou C, Fu H, Lu T, Zhang Y, Yao J, Yang Y. Preconditioning of umbilical cord-derived mesenchymal stem cells by rapamycin increases cell migration and ameliorates liver ischaemia/reperfusion injury in mice via the CXCR4/CXCL12 axis. Cell Prolif. 2019 Mar;52(2):e12546. (IF: 8.755,共一第二)

13. Cheng Y*, Li H*, Deng Y*, Tai Y, Zeng K, Zhang Y, Liu W, Zhang Q#, Yang Y#. Cancer associated fibroblasts induce PDL1+neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis. 2018 Mar 19;9(4):422. (IF:9.685,共一第二)

14. Chen J*, Sun S*, Li H*, Cai X, Wan C. IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis. Front Immunol. 2024 Mar 25;15:1373321.

 

二、承担和参与的科学研究项目

[1] 国家自然科学基金青年项目,,NAT10通过介导CTNNB1的ac4C乙酰化修饰促进肝内胆管细胞癌转移的机制研究(82203823);项目负责人(2023.1-2025.12)

[2] 中国博士后科学基金特别资助项目(站前),METTL3通过m6A甲基化修饰调控circKANSL1编码蛋白促进肝癌转移的机制研究(2022TQ0393);项目负责人(2022.9-2024.4)

[3] 中国博士后科学基金面上项目,m6A甲基化修饰调控的circPICALM通过编码蛋白促进肝内胆管细胞癌转移的机制研究(2023M730436);项目负责人(2023.6-2024.4)

[4] 新重庆青年创新人才项目,假尿嘧啶修饰调控肝癌转移的机制研究(CSTB2024NSCQ-QCXMX0051);项目负责人(2025.1-2027.12)

三、相关奖励与荣誉

[1] 2024“一带一路”肝脏微创技术手术视频比赛全国冠军

[2] 2023重庆市沙坪坝区十佳科技青年

[3] 2023重庆大学青年五四奖章